{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:03:13Z","timestamp":1793037793720,"version":"4.5.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by the proliferation of tumor cells within the lumina of small vessels in systemic organs. Diagnosis remains challenging due to the frequent presentation of non-specific symptoms such as fever and general malaise. Since its listing as a distinct disease entity in the 4th edition of the World Health Organization classification, awareness of IVLBCL has increased, leading to improvements in diagnostic accuracy. Nevertheless, patients with delayed or difficult diagnosis continue to be reported. Recent genetic studies have identified recurrent genetic abnormalities associated with IVLBCL, and the potential utility of liquid biopsy for diagnosis and treatment monitoring has been suggested. However, despite these advances, a gap remains between translational research and clinical application, particularly regarding how liquid biopsy can be incorporated into clinical practice. Regarding treatment, although standard chemotherapy with central-nervous-system-directed therapy has demonstrated favorable outcomes in initial management, the efficacy and safety of emerging immune cell therapies in IVLBCL remain largely unknown. This article aims to review recent advances in the understanding and management of IVLBCL, with the ultimate goal of improving clinical outcomes and advancing therapeutic management of IVLBCL.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf112","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:20:07Z","timestamp":1750663207000},"page":"1201-1209","source":"Crossref","is-referenced-by-count":6,"title":["Recent advances in understanding and management of intravascular large B-cell lymphoma"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-9219","authenticated-orcid":false,"given":"Kazuyuki","family":"Shimada","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025110905440238100_ref1","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: Proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025110905440238100_ref2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(09)70140-8","article-title":"Presentation and management of intravascular large B-cell lymphoma","volume":"10","author":"Shimada","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025110905440238100_ref3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025110905440238100_ref4","first-page":"520","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Jong","year":"2024"},{"key":"2025110905440238100_ref5","first-page":"359","article-title":"On the recognition of systematized endotheliomatosis of the cutaneous blood vessels reticuloendotheliosis?","volume":"10","author":"Pfleger","year":"1959","journal-title":"Hautarzt"},{"key":"2025110905440238100_ref6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00737074","article-title":"Cellular characteristics of neoplastic angioendotheliosis. An immunohistological marker study of 6 cases","volume":"407","author":"Mori","year":"1985","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"2025110905440238100_ref7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00000478-198602000-00004","article-title":"Evidence in favor of its reclassification as ``intravascular lymphomatosis''","volume":"10","author":"Wick","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"2025110905440238100_ref8","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/1097-0142(19821015)50:8&lt;1506::AID-CNCR2820500810&gt;3.0.CO;2-3","article-title":"Histiocytic lymphoma and malignant angioendotheliomatosis: One disease or two?","volume":"50","author":"Ansell","year":"1982","journal-title":"Cancer"},{"key":"2025110905440238100_ref9","first-page":"177","volume-title":"World Health Organization: Pathology and genetics of Tumors of haematopoietic and lymphoid tissues","author":"Gatter","year":"2001"},{"key":"2025110905440238100_ref10","first-page":"252","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Nakamura","year":"2008"},{"key":"2025110905440238100_ref11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/10428199909058451","article-title":"An Asian variant of intravascular lymphomatosis: An updated review of malignant histiocytosis-like B-cell lymphoma","volume":"33","author":"Murase","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2025110905440238100_ref12","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1200\/JCO.1994.12.12.2573","article-title":"Intravascular lymphomatosis: A clinicopathologic study of 10 cases and assessment of response to chemotherapy","volume":"12","author":"DiGiuseppe","year":"1994","journal-title":"J Clin Oncol"},{"key":"2025110905440238100_ref13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/10428199909058485","article-title":"Intravascular large cell lymphoma: Clinicopathological, immuno-histochemical and molecular genetic studies","volume":"34","author":"Kanda","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"2025110905440238100_ref14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1046\/j.1365-2559.2000.00980.x","article-title":"Intravascular large B-cell lymphoma with bone marrow involvement at presentation and haemophagocytic syndrome: Two western cases in favour of a specific variant","volume":"37","author":"Dufau","year":"2000","journal-title":"Histopathology"},{"key":"2025110905440238100_ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1287363","article-title":"Intravascular large B-cell lymphoma in the United States (US): A population-based study using surveillance, epidemiology, and end results program and National Cancer Database","volume":"58","author":"Rajyaguru","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025110905440238100_ref16","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1002\/cam4.4742","article-title":"Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study","volume":"11","author":"Bonnet","year":"2022","journal-title":"Cancer Med"},{"key":"2025110905440238100_ref17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the `cutaneous variant'","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref18","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2007.15.4278","article-title":"Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan","volume":"26","author":"Shimada","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025110905440238100_ref19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025110905440238100_ref20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00277-023-05525-7","article-title":"Distinct FDG PET\/CT avidity among newly diagnosed intravascular large B-cell lymphoma patients: A descriptive observational study","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"key":"2025110905440238100_ref21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bjh.15923","article-title":"Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States","volume":"186","author":"Geer","year":"2019","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref22","first-page":"826","article-title":"An Asian variant of intravascular large B-cell lymphoma: Clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome","volume":"111","author":"Murase","year":"2000","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2025110905440238100_ref24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"2025110905440238100_ref25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0046-8177(00)80223-3","article-title":"Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis","volume":"31","author":"Ponzoni","year":"2000","journal-title":"Hum Pathol"},{"key":"2025110905440238100_ref26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5414\/CNP65222","article-title":"Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab","volume":"65","author":"Kusaba","year":"2006","journal-title":"Clin Nephrol"},{"key":"2025110905440238100_ref27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nprot.2007.25","article-title":"Establishment of human tumor xenografts in immunodeficient mice","volume":"2","author":"Morton","year":"2007","journal-title":"Nat Protoc"},{"key":"2025110905440238100_ref28","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"key":"2025110905440238100_ref29","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"2025110905440238100_ref30","doi-asserted-by":"publisher","first-page":"13054","DOI":"10.1038\/srep13054","article-title":"Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells","volume":"5","author":"Sugimoto","year":"2015","journal-title":"Sci Rep"},{"key":"2025110905440238100_ref31","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/leu.2016.67","article-title":"Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma","volume":"30","author":"Shimada","year":"2016","journal-title":"Leukemia"},{"key":"2025110905440238100_ref32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12185-023-03604-z","article-title":"Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice","volume":"118","author":"Sahashi","year":"2023","journal-title":"Int J Hematol"},{"key":"2025110905440238100_ref33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): A clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"key":"2025110905440238100_ref34","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood.2020007245","article-title":"Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma","volume":"137","author":"Shimada","year":"2021","journal-title":"Blood"},{"key":"2025110905440238100_ref35","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.3324\/haematol.2017.178830","article-title":"Liquid biopsy for the identification of intravascular large B-cell lymphoma","volume":"103","author":"Suehara","year":"2018","journal-title":"Haematologica"},{"key":"2025110905440238100_ref36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/PAS.0000000000001978","article-title":"Intravascular large B-cell lymphoma genomic profile is characterized by alterations in genes regulating NF-kappaB and immune checkpoints","volume":"47","author":"Gonzalez-Farre","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"2025110905440238100_ref37","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"key":"2025110905440238100_ref38","doi-asserted-by":"publisher","first-page":"e18576","DOI":"10.1111\/jcmm.18576","article-title":"Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA","volume":"28","author":"Chen","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2025110905440238100_ref39","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"2025110905440238100_ref40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"2025110905440238100_ref41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/pin.12742","article-title":"Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma","volume":"69","author":"Suzuki","year":"2019","journal-title":"Pathol Int"},{"key":"2025110905440238100_ref42","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1002\/cam4.3104","article-title":"PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy","volume":"9","author":"Suzuki","year":"2020","journal-title":"Cancer Med"},{"key":"2025110905440238100_ref43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/his.13870","article-title":"A study of PD-L1 expression in intravascular large B cell lymphoma: Correlation with clinical and pathological features","volume":"75","author":"Gupta","year":"2019","journal-title":"Histopathology"},{"key":"2025110905440238100_ref44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/cas.16310","article-title":"Spheroid culture to select theoretical therapeutic drugs in intravascular large B-cell lymphoma","volume":"116","author":"Takai","year":"2025","journal-title":"Cancer Sci"},{"key":"2025110905440238100_ref45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/bjh.16081","article-title":"Diagnosis of intravascular large B cell lymphoma: Novel insights into clinicopathological features from 42 patients at a single institution over 20 years","volume":"187","author":"Matsue","year":"2019","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bjd.17603","article-title":"Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients","volume":"181","author":"Enzan","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025110905440238100_ref47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00277-010-1101-3","article-title":"Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma","volume":"90","author":"Matsue","year":"2011","journal-title":"Ann Hematol"},{"key":"2025110905440238100_ref48","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0025-6196(11)61097-5","article-title":"Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma","volume":"82","author":"Asada","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2025110905440238100_ref49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0002-9343(02)01378-5","article-title":"Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin","volume":"114","author":"Gill","year":"2003","journal-title":"Am J Med"},{"key":"2025110905440238100_ref50","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood-2018-11-887570","article-title":"Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma","volume":"133","author":"Matsue","year":"2019","journal-title":"Blood"},{"key":"2025110905440238100_ref51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00277-021-04572-2","article-title":"Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone","volume":"101","author":"Hosoi","year":"2022","journal-title":"Ann Hematol"},{"key":"2025110905440238100_ref52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2169\/internalmedicine.47.0808","article-title":"Successful treatment of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy and FDG-PET scan","volume":"47","author":"Takahashi","year":"2008","journal-title":"Intern Med"},{"key":"2025110905440238100_ref53","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2141.2012.09237.x","article-title":"FDG-PET guided diagnosis of vaginal intravascular diffuse large B-cell lymphoma","volume":"158","author":"Hemmaway","year":"2012","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12149-012-0600-9","article-title":"Intravascular large B-cell lymphoma with diffuse FDG uptake in the lung by 18FDG-PET\/CT without chest CT findings","volume":"26","author":"Yamashita","year":"2012","journal-title":"Ann Nucl Med"},{"key":"2025110905440238100_ref55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1102\/1470-7330.2012.0002","article-title":"Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: A case report and a discussion of the causes of diffuse FDG uptake in the lungs","volume":"12","author":"Wagner","year":"2012","journal-title":"Cancer Imaging"},{"key":"2025110905440238100_ref56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hon.876","article-title":"Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT\/(67)gallium scintigraphy abnormality","volume":"27","author":"Kitanaka","year":"2009","journal-title":"Hematol Oncol"},{"key":"2025110905440238100_ref57","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/annonc\/mdh274","article-title":"Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma","volume":"15","author":"Ferreri","year":"2004","journal-title":"Ann Oncol"},{"key":"2025110905440238100_ref58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.35772\/ghm.2024.01021","article-title":"Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma","volume":"6","author":"Sakai","year":"2024","journal-title":"Glob Health Med"},{"key":"2025110905440238100_ref59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","article-title":"The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in `western' patients with intravascular large B-cell lymphoma","volume":"143","author":"Ferreri","year":"2008","journal-title":"Br J Haematol"},{"key":"2025110905440238100_ref60","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1200\/JCO.2008.19.1841","article-title":"Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?","volume":"26","author":"Ferreri","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025110905440238100_ref61","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/j.1349-7006.2010.01555.x","article-title":"Central nervous system involvement in intravascular large B-cell lymphoma: A retrospective analysis of 109 patients","volume":"101","author":"Shimada","year":"2010","journal-title":"Cancer Sci"},{"key":"2025110905440238100_ref62","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1111\/cas.15091","article-title":"Current progress and future perspectives of research on intravascular large B-cell lymphoma","volume":"112","author":"Shimada","year":"2021","journal-title":"Cancer Sci"},{"key":"2025110905440238100_ref63","doi-asserted-by":"publisher","first-page":"103078","DOI":"10.1016\/j.eclinm.2025.103078","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): Long-term results of a multicentre, single-arm, phase 2 trial","volume":"80","author":"Shimada","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2025110905440238100_ref64","first-page":"100401","article-title":"Intravascular large B-cell lymphoma masquerading as stroke successfully treated with R-hyper-CVAD","volume":"21","author":"Popiolek","year":"2024","journal-title":"Leuk Res Rep"},{"key":"2025110905440238100_ref65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jha2.380","article-title":"Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: A single institution's experience","volume":"3","author":"Takahashi","year":"2022","journal-title":"EJHaem"},{"key":"2025110905440238100_ref66","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to Ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025110905440238100_ref67","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025110905440238100_ref68","doi-asserted-by":"publisher","first-page":"vdae037","DOI":"10.1093\/noajnl\/vdae037","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2025110905440238100_ref69","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"2025110905440238100_ref70","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/bmt.2016.339","article-title":"Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: The European Society for Blood and Marrow Transplantation experience","volume":"52","author":"Meissner","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2025110905440238100_ref71","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41409-019-0491-7","article-title":"Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult lymphoma working Group of the Japan Society for hematopoietic cell transplantation","volume":"54","author":"Kato","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2025110905440238100_ref72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110905440238100_ref73","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from Polatuzumab Vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110905440238100_ref74","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/2159-8290.CD-23-0802","article-title":"Molecular determinants of sensitivity to Polatuzumab Vedotin in diffuse large B-cell lymphoma","volume":"14","author":"Corcoran","year":"2024","journal-title":"Cancer Discov"},{"key":"2025110905440238100_ref75","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110905440238100_ref76","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"2025110905440238100_ref77","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025110905440238100_ref78","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/11\/1201\/63711831\/hyaf112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/11\/1201\/63711831\/hyaf112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T10:44:09Z","timestamp":1762685049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/11\/1201\/8195400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf112","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,9]]}}}